INIS
bladder
100%
tyrosine
100%
kinases
100%
receptors
100%
cancer
100%
muscles
58%
tumors
23%
phosphorylation
23%
toxicity
17%
data
17%
proposals
11%
organoids
11%
phagocytes
11%
patients
11%
therapy
11%
gain
11%
dendrites
11%
accumulation
5%
diseases
5%
drugs
5%
elderly people
5%
clearance
5%
mice
5%
management
5%
control
5%
transcription factors
5%
blocking
5%
research programs
5%
concentration
5%
cell membranes
5%
populations
5%
guidelines
5%
increasing
5%
clinical trials
5%
migration
5%
matrices
5%
ligands
5%
inhibition
5%
kazakhstan
5%
cost
5%
aging
5%
molecules
5%
environment
5%
regulations
5%
urinary tract
5%
Keyphrases
AXL Receptor
100%
Muscle-invasive Bladder Cancer
50%
Bladder Cancer
50%
Receptor Tyrosine Kinase
50%
Mechanotransduction
50%
Phosphorylation
20%
Bladder Cancer Cells
10%
EGFR-MAPK
10%
YAP Activation
10%
Phagocytes
10%
A-loop
10%
Efferocytosis
10%
Molecular Pathways
10%
Cytotoxicity
10%
Cancer Cells
10%
Dendritic Cells
10%
MAPK Signaling
10%
Therapeutic Target
5%
Patient-derived Organoids
5%
Micromolar Concentration
5%
Organoid Culture
5%
Epithelial-mesenchymal Transition
5%
Common Cancers
5%
Gemcitabine
5%
Poor Prognosis
5%
Prolonged Exposure
5%
Professional Phagocytes
5%
Cell Processes
5%
Aging Population
5%
International Guidelines
5%
Unmet Needs
5%
Tumor Organoids
5%
Treatment Scheme
5%
AXL Inhibitor
5%
Oncology
5%
Cell Survival Pathways
5%
Combination Therapy
5%
Cancer Tumor
5%
Elderly People
5%
Cell Migration
5%
YAP-TEAD
5%
Some Element
5%
Cancer Types
5%
Tumor Microenvironment
5%
Tumor
5%
Insults
5%
Small Molecule Inhibitors
5%
Toxic Environment
5%
Mechanistic Studies
5%
Urinary Tract
5%
Drug Resistance
5%
Extracellular Matrix
5%
Cisplatin
5%
Novel Treatments
5%
Pharmacological Inhibitors
5%
Apoptotic Cell Clearance
5%
Mouse Model
5%
Incidence Rate
5%
Therapy Resistance
5%
Kazakhstan
5%
Therapy Approaches
5%
Clinical Trials
5%
Cell Membrane
5%
Physiological Condition
5%
Collaborative Research
5%
Transcription Factor Complex
5%
Median Survival
5%
Medicine and Dentistry
Kinase Signaling
50%
Mechanotransduction
50%
Receptor
50%
Bladder Cancer
50%
Muscle Invasive Bladder Cancer
50%
Protein Tyrosine Kinase
50%
Cancer Cell
20%
Neoplasm
15%
Gemcitabine
10%
Chemotherapy
10%
Malignant Neoplasm
10%
Dendritic Cell
10%
MAPK Signaling
10%
Efferocytosis
10%
Organoid
10%
Cytotoxicity
10%
Epidermal Growth Factor Receptor
10%
Tumor Microenvironment
5%
Clinical Trial
5%
Cell Migration
5%
Drug Resistance
5%
Extracellular Matrix
5%
Cell Survival
5%
Cell Membrane
5%
Oncology
5%
Therapy Resistance
5%
Diseases
5%
Long Term Exposure
5%
Reproducibility
5%
Cancer Types
5%
Mesenchymal-Epithelial Transition
5%
Combination Therapy
5%
Urinary Tract
5%
Transcription Factors
5%
Cisplatin
5%
Health Care Cost
5%